Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.

@article{Nakayamada2004EtidronatePH,
  title={Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.},
  author={Shingo Nakayamada and Yosuke Okada and Kazuyoshi Saito and Yoshiya Tanaka},
  journal={The Journal of rheumatology},
  year={2004},
  volume={31 1},
  pages={163-6}
}
OBJECTIVE To assess the efficacy of etidronate and alfacalcidol in preventing glucocorticoid induced bone loss in premenopausal women and men starting high dose glucocorticoid therapy. METHODS Premenopausal women (n = 16) and men (n = 5) who had just developed autoimmune diseases, and who agreed to use high dose glucocorticoid therapy for the first time, were randomized to receive alfacalcidol (1 micro g/day) alone (alfacalcidol group, n = 11); or alfacalcidol (1 micro g/day) and intermittent… CONTINUE READING